High expression of DCUN1D5 are closely associated with tumor invasion and proliferation and Knockdown of DCUN1D5 was found to inhibit the proliferation, migration, and invasion of HCC cells and increases its free fatty acid accumulation.
Abstract
Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with limited reliable biomarkers for early diagnosis and prognosis. In this study, we explored the role of DCUN1D5, a potential biomarker, in HCC. Methods We performed integrated bioinformatics analyses of publicly available HCC datasets, including TCGA, GEO, and ICGC, followed by in vitro experiments on HCC cell lines to validate our findings. Results DCUN1D5 expression was significantly elevated in HCC tissues compared to normal liver tissues. High DCUN1D5 levels were associated with poor prognosis and advanced tumor stage in HCC patients. Additionally, bioinformatics analysis revealed a correlation between DCUN1D5 expression levels and both immune infiltration and immunotherapy response in hepatocellular carcinoma. Functional assays revealed that DCUN1D5 knockdown inhibited cell proliferation, migration, and invasion in HCC cells. Mechanistically, Enrichment analysis revealed significant correlations between DCUN1D5 and multiple biological pathways; specifically, we observed a negative correlation between the expression level of DCUN1D5 and fatty acid metabolism. Further cellular experiments demonstrated that knockdown of DCUN1D5 can induce accumulation of free fatty acids in hepatocellular carcinoma cells. Conclusion In summary, our study identified DCUN1D5 as a potential biomarker for poor prognosis in HCC, high expression of DCUN1D5 are closely associated with tumor invasion and proliferation. Knockdown of DCUN1D5 was found to inhibit the proliferation, migration, and invasion of HCC cells and increases its free fatty acid accumulation. These studies suggest new possibilities for treatment strategies for HCC.
Functional data link LINC02163 expression to HCC cell growth, PI3K/AKT pathway activity, and changes in stemness-related markers, although the underlying mechanism remains to be established.
Clinical, histopathological, and loss-of-function findings support further investigation of CARS1 as a prognostic marker and candidate therapeutic target in HCC, although additional mechanistic and in vivo validation is required.
Ye-Zhen Tang, Ke-Jun Liu, Zhen-Ya Tan et al.· Frontiers in Bioscience· 0 citations
DBF4B holds promise as both a prognostic biomarker and a novel therapeutic target for HCC after functional experiments demonstrated that silencing DBF4B markedly suppressed the proliferative and migratory capabilities of HCC cells.
Bing Dong, Pengju Xi, Guang-Xin Yang et al.· Molecular Biology Reports· 0 citations
PURPOSE
Hepatocellular carcinoma (HCC) is an aggressive malignancy with limited therapeutic options and poor prognosis, highlighting the need for prognostic biomarkers and novel molecular candidates. This study aimed to identify chaperonin-related genes associated with HCC prognosis and to preliminarily explore the bio...
Li Su, Meng-Si Wu, Hua Liu et al.· Gene· 0 citations
This study establishes a robust LRL-based prognostic model and identifies AC026412.3 as a key regulator of lipid metabolic reprogramming via the SLC22A5–fatty acid β-oxidation axis, highlighting its potential as a biomarker and therapeutic target in HCC.
Li-Xin Liu, Yu-Hao Fan, Hao Zou et al.· Journal of Clinical and Tran...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.